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Summary. Acute coronary syndromes account worldwide
for a significant burden of hospital- and societal costs.
Pharmacotherapy of acute coronary syndromes consists of
a combined antithrombotic therapy. Remarkable therapeu-
tic advances have been made with the introduction of glyco-
protein IIb/IIIa receptor inhibitors, low molecular weight
heparins and thienopyridines, such as clopidogrel. Based
on positive clinical data of large randomized trials numer-
ous cost studies have been undertaken to analyse the cost-
effectiveness of these new drugs. Most of them are show-
ing an acceptable level of cost-effectiveness for the new
treatments. Taking all available cost-studies into account,
we conclude that new antithrombotic treatments are cost-
effective as long as their use is limited to selected patient
populations.
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Acute Coronary Syndrome: Burden
of Disease
Acute coronary syndrome (ACS) is a term used to de-
scribe a spectrum of conditions associated with my-
ocardial ischemia such as unstable angina (UA) and
myocardial infarction (MI) (non-Q-wave, Q-wave and
non-ST-segment elevation) [1]. Pathogenesis of ACS
mainly results from arteriosclerosis of the coronary
arteries and occlusive local thrombosis due to a rup-
tured plaque [2]. According to the World Health Or-
ganisation ischemic heart disease accounts for 12.6%
of all deaths worldwide. In Europe the mortality rate
of coronary artery disease (CAD) significantly varies
in different countries with the highest rate in Eastern
Europe. Although the mortality rate has been decreas-
ing during the last years, the prevalence of patients
with cardiovascular disease will increase due to an in-
creased life expectancy.
In the past, several studies attempted to estimate
the direct medical costs derived from treating ACS. In
1982 Charles et al. already published a paper analysing
direct and indirect costs of medical and surgical treat-
ment in patients with CAD [3].
Based on medical decision algorithms, Wittels et al.
calculated expenses of different events resulting from
CAD in the United States of America [4]. Charges
were obtained from medical-care prices of different
coronary care facilities. Average diagnosis- and treat-
ment disbursements over a 5-year period, in 1986
prices, for acute MI were estimated at 51.211 US
$ per patient, for angina pectoris 24.980 US $, UA
40.581 US $, sudden death 9078 US $ and non-sudden
death 19.697 US $ respectively. Russell et al. used a
Markov-Model to calculate direct medical costs in the
USA [5]. Yearly total direct spending for diagnosis and
treatment of patients with CAD in the USA was 16.2
billion US $ in 1995 prices. In Switzerland Sagmeis-
ter et al. attempted to analyse both direct and indi-
rect medical costs (i.e. productivity losses) [6]. Total
expenditures of ischemic heart disease in Switzerland
in 1993 amounted to 2.1 billion CHF (1.45 billion US
$). Indirect costs contributed approximately 47% to to-
tal costs. Expenses due to morbidity, disability and
premature death were the major components of indi-
rect costs. Direct costs were caused primarily by in-
patient care, secondarily by outpatient care and only
a low percentage by rehabilitation. Comparing the de-
velopment of charges over a 5 year period (1988–1993)
per patient, the authors concluded that spending for
in- and outpatient treatment increased more than 50%,
whereas indirect costs slightly decreased. This phe-
nomenon is thought to be related to the introduction
of novel, more effective diagnostic and therapeutic op-
tions that are more expensive but seem to result in a
more favourable morbidity and lower mortality.
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Costs of Different Treatments for Acute
Coronary Syndrome
The treatment of ACS consists of inpatient diagnosis
and inpatient treatment usually done in an emergency
room and intensive care unit and a long term secondary
prophylaxis of the underlying condition, CAD. There-
fore, efficacy of different treatments and their implica-
tion on costs have to be examined over a long time pe-
riod. The cost perspective (hospital, society, country) is
another important point. In each country there are dif-
ferent charges for drugs, medical procedures and hos-
pitalisation; varying drug-costs may result in a more
or less cost-effective ratio of a given treatment. Fur-
thermore, not only direct medical costs, but also impli-
cations on indirect costs should be taken into account
when measuring cost-effectiveness of treatments.
Brown et al. analysed the direct medical treatment
costs for ACS in different countries in the initial hospi-
talisation phase as well as during subsequent hospital-
isations for the same condition over a 6 month period
[7]. They found differences in the following European
countries due to levels of charges (Figure 1), but also
to unequal utilisation rate of expensive cardiac arteri-
ography and angioplasty.
Recommended pharmacological treatments target-
ing the thrombotic process in ACS include acetyl-
salicylic acid (ASA), glycoprotein IIb/IIIa-receptor
(GPIIb/IIIa) inhibitors, thienopyridines and heparins
[8]. The role of ASA in treatment of ACS is sup-
ported by abundant evidence and should be given as
a standard treatment according to international guide-
lines [9]. Low treatment costs per patient and per day
(0.04 US $) [10] and proven efficacy for ASA result in a
very cost-effective ratio. The treatment of a whole pop-
ulation with daily ASA until death or over a 25 year pe-
riod has an attractive cost-effectiveness of 11’000 US $
per quality-adjusted year of life gained (QALY) versus
no secondary prophylaxis for patients with CAD [10].
GPIIb/IIIa- inhibitors are a new class of antithrom-
botic agents and are mainly used in addition to ASA
in patients in whom a percutaneous coronary inter-
vention is performed or in non ST-segment elevation
MI. Efficacy has been documented in several large ran-
domised controlled trials [11–19]. Based on data from
these studies several modes were designed to analyse
the cost-effectiveness (Table 1). Most of them show an
economical advantage compared to other cardiovascu-
lar therapies. The cost-effectiveness studies are sum-
marized in Table 1. As shown in this table, published
cost-effectiveness data must be interpreted cautiously
because of different follow up periods, different origins
of cost data and different expressions of cost effective-
ness (costs per life year gained, costs per prevented
death of MI, costs per life years saved and incremental
costs, etc.). Most of these studies were based on effec-
tiveness data of the PURSUIT trial [16]. Generalizing
these results to a whole population and applying the
costs to different countries should be undertaken very
cautiously. Nevertheless, research in the field of phar-
macoeconomics is important in an area of development
of new innovative but expensive therapies.
In conclusion, the efficacy and safety of GPIIb/IIIa
inhibitors therapy as an adjunct of the treatment of
non-ST-segment elevation ACS is widely accepted,
based on large clinical data. In this class of antithrom-
botic agents costs remains a major issue. Acquisition
costs of GPIIb/IIIa inhibitors are higher than the tra-
ditional agents (700–1700 US $ per infusion [20]), but
cost-effectiveness data show that their incremental
costs can be within the widely accepted ranges for new
therapies. The main cost drivers of complications after
ACS are the charges for rehospitalisation and revas-
cularisation, that could be reduced with the addition
of GPIIb/IIIa inhibitors to standard treatment. High
acquisition expenses for this agents could be there-
fore offset by reduction of hospitalisations and treat-
ment spending. However, there are several limitations
Fig. 1. Average per patient initial- and subsequent hospital cost for the treatment of acute coronary syndrome7.
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Table 1. Cost-effectiveness studies in treatment of acute coronary syndrome with glycoprotein IIb/IIIa inhibitors
Author, year
Country,
currency Drug
Calculated time
period
Source of clinical
data Cost perspective
Cost-
effectiveness
ratio in €∗
Hillegass, 1999 [20] USA, US $ eptifibatide and
tirofiban
30 days PRISM,
PRISM-PLUS,
PURSUIT
Health care
provider
32.000–82.000
per death or
MI prevented
Mark, 2000 [21] USA, US $ eptifibatide 6 months and
lifetime
PURSUIT Societal 16.491 LYG
McElwee, 1997 [22] USA, US $ abciximab Lifetime IMPACT-II,
EPIC,CAPTUE,
GUSTO
Health care
provider
20.000 LYG
Bell, 1999 [23] USA, US $ abciximab,
tirofiban,
eptifibatide
30 days PURSUIT,
PRISM-PLUS,
Health care
provider
40.000-46.000 per
death or MI
prevented
Szucs, 1999 [24] Switzerland,
CHF
tirofiban 7 days PRISM-PLUS Health care
provider
366 saved per
patient
Szucs, 2003 [25] Germany, € eptifibatide 7 days PURSUIT Health care
provider
14.464 LYG
Brown, 2002 [7] Germany, UK,
France, Italy,
Netherlands,
Spain, €
eptifibatide 6 months PURSUIT Health care
provider
7.285-13.742
LYG
LYG= life years gained.
∗Converted to € based yearly discount rate of 3% and 2004 currency exchange rates.
Table 2. Cost-effectiveness studies in treatment of acute coronary syndrome with Enoxaparin
Author, year Country currency
Source of clinical
data Cost perspective
Total savings per
patient after 30
days in €∗
Total saving per
patient after 1 year
in €∗
Brosa, 2002 [28] Spain, € ESSENCE (TIMI
11B)
Health care provider 448 660
Mark DB, 1998 [29] USA, US $ ESSENCE Health care provider 1172 No data
O’Brien, 2000 [30] Canada, US $ ESSENCE Health care provider No data 1485
Duteournay, 2000 [31] France, € ESSENCE Health care provider 427 No data
∗Converted to € based yearly discount rate of 3% and 2004 currency exchange rates.
to these studies. The time period chosen for the end-
points of the clinical studies (death and MI) is mostly
limited to the hospitalisation time (7 days). The per-
spective of these cost-effectiveness studies is there-
fore limited to health care providers (hospital) and to
direct medical costs. The long term socio-economic im-
pact on the whole health care system of these new an-
tithrombotic agents still has to be examined, as long
term mortality, long term rehospitalisations and the
associated indirect costs could significantly influence
the cost-effectiveness of these drugs.
For heparins cost data mainly exist on cost-
effectiveness of low molecular weight heparins
(LMWH) versus the standard treatment with un-
fractionated heparin. Advantages of LMWH over
unfractionated heparin include convenience of admin-
istration, higher bioavailability and the lack of need
for monitoring. The most studied LMWH for ACS is
enoxaparin, which was found to reduce the incidence
of death, myocardial reinfarction and recurrent angina
in patients with ACS compared with unfractionated
heparin [26,27] (Table 2). Based on these trials, cost
studies conducted in different countries suggest that
enoxaparin is a less expensive treatment for the
secondary prevention of ACS due to superior efficacy
and lower total treatment and follow-up costs. The
acquisition and administrative expenses of enoxaparin
are higher than for unfractionated heparin. In Spain,
for example, daily costs for enoxaparin treatment
amount to 14.6 € compared to 0.64 € for unfractionated
heparin [28]. But the reduced need for hospitalisation
and revascularization over a period of 1 year amortises
this initial difference in cost.
Clinical Profile of Clopidogrel
Clopidogrel, a thienopyridine antiplatelet agent, is
an adenosine diphosphate (ADP)-receptor antagonist.
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Table 3. CURE (Clopidogrel in unstable angina to prevent
recurrent events trial): Main results
ASA
(n=6303)
ASA plus
clopidogrel
(n=6259)
Relative
risk P value
CV death, MI,
stroke
(primary end
point) (%)
11.47 9.28 0.80 .00009
CV death (%) 5.49 5.06 0.92 NR
MI (%) 6.68 5.19 0.77 <.001
Stroke (%) 1.4 1.2 0.85 NR
Major bleeding
(%)
2.7 3.6 1.34 .003
ASA= acetylsalicylic acid; CV = cardiovascular; NR = not reported.
Clopidogrel inhibits adenosine diphosphate (ADP)
binding to its platelet receptor and subsequent ADP-
mediated activation of the glycoprotein GPIIb/IIIa
complex, thus inhibiting platelet aggregation. Clopi-
dogrel irreversibly modifies the ADP receptor so
platelets are affected for the remainder of their lifes-
pan. An active metabolite is responsible for the drug’s
activity. Platelet aggregation induced by agonists
other than ADP is also inhibited by blocking the ampli-
fication of platelet activation by released ADP. Doses
of 75 mg per day inhibit platelet aggregation by 40
to 60% at steady state, which occurs within 3 to 7
days.
Cost-effectiveness studies for treatment of
acute coronary syndrome with clopidogrel
In patients with ACS clopidogrel is recommended for
acute as well as longer term treatment for at least 9–
12 months [8]. Beyond this level of evidence, treatment
will depend on the risk status of the patient and indi-
vidual clinical judgement. Clopidogrel may be recom-
mended for immediate and long-term therapy of pa-
tients who do not tolerate ASA, and is recommended
for patients receiving a stent. Clopidogrel has shown
its efficacy for patients with ACS, including also pa-
tients with medical treatment and angioplasty (with
or without stent) or coronary artery bypass grafting.
Clopidogrel has been shown to decrease the rate of
the combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of the combined endpoint
of cardiovascular death, MI, stroke, or refractory is-
chemia [32].
CURE (Clopidogrel in Unstable angina to prevent
Recurrent Events trial) was a study with 12.562 pa-
tients evaluating the efficacy and safety of the an-
tiplatelet agent clopidogrel when administered with
ASA in patients with ACS [32] (Table 3). This random-
ized trial studied the effectiveness and safety of clopi-
dogrel in combination with ASA versus ASA alone
when used for patients with non-ST-segment elevation
ACS. The results indicate that the administration of
clopidogrel in addition to ASA during a period of 3 to
12 months after an acute episode reduces the combined
risk of cardiovascular death, MI, and stroke compared
to ASA alone.
In CURE, clopidogrel when taken daily with ASA
demonstrated a 20% (P = 0.00009) relative risk reduc-
tion in the combined end points of MI, stroke, or car-
diovascular (CV) death with an absolute event rate of
9.3% in the clopidogrel group and 11.4% in the placebo
group. The second primary outcome was a 14% (P =
0.0005) relative risk reduction in the combined end
points of MI, stroke, CV death, or refractory ischemia,
with an absolute event rate of 16.5% in the clopidogrel
group and 18.8% in the placebo group.
Several economic studies addressed clopidogrel in
ACS (Table 4).
Schleinitz et al. undertook a cost-utility analysis for
high-risk acute coronary syndrome patients comparing
combination therapy of clopidogrel and ASA for one
year followed by ASA monotherapy with life long ASA
therapy in patients presenting with unstable angina
and electrographic changes or non-Q-wave myocardial
infarction [33]. The collective treated with ASA alone,
lived 9,51 QALYs after an initial event and gener-
ated costs were 127.700 US $. The addition of clopido-
grel increased life expectancy to 9,61 QALYs and cost
129.300 US $ compared to ASA alone. The QALY for
clopidogrel in combination to ASA compared to ASA
monotherapy resulted in 15.400 US $. The investiga-
tors showed robustness to all sensitivity analyses for
one year. For patients receiving longer combination
therapy the treatment depends critically on the bal-
ance of thrombotic events, continuous efficacy and the
increased bleeding risk of patients ingesting clopido-
grel. In a probabilistic sensitivity analysis incremen-
tal cost-effectiveness ratios (ICERs) above 50.000 US
$ were determined in less than 3% of all simulations.
The authors noted that this investigation would not
apply to patients presenting with severe heart failure
or those undergoing short-term treatment with glyco-
protein IIb/IIIa inhibitors. It would also not apply to
patients who have recently undergone revascularisa-
tion in a patient population receiving long term anti-
coagulation. Schleinitz et al. proved that clopidogrel is
cost-effective in addition to ASA given for one year,
which is in the accepted range for patients with high-
risk acute coronary syndrome. Life expectancy rose
with combination therapy. The authors indicated that
further trials should be performed comparing long-
term period efficacy of clopidogrel in relation to bleed-
ing risk before an extended therapy is established.
Lamy et al. undertook an economic analysis of the
use of clopidogrel in the UK, USA, Sweden, France
and Canada based on the CURE study [34]. Their hy-
pothesis was that clopidogrel is more expensive but
also more effective than placebo. The group performed
an incremental cost-effectiveness analysis, comparing
the differences in costs and effectiveness between in-
tervention and no intervention. The authors used the
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Table 4. Overview of cost-effectiveness studies of clopidogrel for treatment of acute coronary syndrome
Author Year publ. Country
Calculated time
period
Source of clinical
data Cost perspective
Cost
effectiveness
ratios in €∗
Schleinitz et al. [33] 2005 USA lifetime CURE societal 17.423 € per
QALY
Lamy et al. [34] 2004 UK 9 months CURE 16.847 € PPLE
USA 25.437 € PPLE
Sweden 13.857 € PPLE
France 16.186 € PPLE
Canada 5.585 € PPLE
Lindgren et al. [35] 2004 Sweden 12 months CURE societal 1.009–1.365 € per
LYG
Latour-Perez [36] 2004 Spain 12 months CURE 12.000 € per
QALY
Frei [37] 2004 Switzerland 9 months CURE 2.540 € per LYG
Bru¨ggenju¨rgen [38] 2003 Germany 9 months CURE 13.134–23.035 €
PPLE
Schwarz [39] 2004 Austria 9 months CURE 4.146 € per LYG
PPLE = per prevented life-threatening event; LYG = life years gained; QALY = quality-adjusted life years.
∗Converted to € based yearly discount rate of 3% and 2005 currency exchange rates.
Table 5. Overview of cost-effectiveness studies for secondary prevention of acute coronary syndrome
Author Year publ. Country
Calculated time
period
Source of clinical
data Cost perspective
Cost
effectiveness
ratios
Gaspoz [10] 2002 USA 25 years Coronary Heart
Disease Model
114’000 US $
QALY
Haldemann [42] 2001 Switzerland 1.9 years CAPRIE 22837 CHF LYG
Schleinitz [43] 2004 USA Life time
treatment
CAPRIE 25100 US $
QALY
LYG = life years gained, QALY = quality-adjusted life years.
placebo collective result as proxy for no intervention.
The costs included were direct medical care charges
for drugs and hospitalisation. The Cure trial did nei-
ther contain data to account direct costs associated
with testing or visits of outpatients nor indirect costs
due to loss of productiveness. For Canada the investi-
gators relied on a detailed case costing system to reg-
ister all procedures, investigations and drugs at the
specific length of stay in the study. For all other coun-
tries the DRG-system (diagnosis related groups) was
used where all resources are merged in a single code.
The average amount for each treatment group was cal-
culated and reported in local currency for the corre-
sponding country. For initial hospitalisation the aver-
age costs were reduced for the clopidogrel group in
all countries while the follow up costs and finally the
total costs were significantly higher with clopidogrel
compared to placebo. Difference in costs (95% CI): UK
208 £ (119, 297); USA 451 US $ (58, 845); Sweden 2571
SKr (728, 4412); France 325 € (85, 565); Canada 161
CAN $ (−185, 506). With an absolute reduction of total
primary events of 2.0% for clopidogrel an incremental
cost-effectiveness (ICER) of 10.366 £ (UK), 22.484 US
$ (USA), 127.951 SKr (Sweden), 16.186 € (France) and
7.973 CAN $ (Canada) resulted. Lamy et al. concluded
that there is a favourable incremental cost effective-
ness ratio (ICER) for clopidogrel compared to other
medical therapies. Clopidogrel reduced the initial and
subsequent hospitalisation expenses but the acquisi-
tion cost during the follow up phase resulted in an
overall rise of direct costs. The duration of the therapy
should be individualised depending on patients’ profile,
alternative therapy options and country-specific eco-
nomic status.
The cost-effectiveness of clopidogrel in ACS was
recently examined in Sweden by Lindgren et al. [35]
The investigators attempted to evaluate the long-term
cost-effectiveness of clopidogrel in addition to stan-
dard therapy (including ASA) in patients with ACS
without ST-segment elevation. They aimed at evaluat-
ing the cost-effectiveness in terms of cost per life year
gained (LYG) of clopidogrel treatment in Sweden. The
incremental cost-effectiveness ratios (ICER) were as-
sessed by using a Markov model with transition proba-
bilities estimated from the Swedish hospital discharge
and death registers. The patients were assumed to be
treated for one year, with treatment effects and drug
costs taken from the CURE trial.
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They found an incremental cost-effectiveness ratio
of 1.365 € per life year gained (CURE trial population
including direct and indirect costs). For the population
similar to the Swedish death register the ratio showed
1.009 €. The authors reasoned that adding clopidogrel
to standard therapy including ASA is cost-effective
in the studied setting and compares favourably with
other cardiovascular treatment and prevention strate-
gies.
Latour-Perez et al. established a cost model for
cost-effectiveness of clopidogrel in non-ST-segmental
elevation ACS in Spain over one year [36]. Based on
the Cure- and the Framingham study a Markov deci-
sion tree was developed taking into account the Span-
ish age-specific mortality rates in the national public
health system. Using national diagnosis related groups
to reflect the costs of one year of treatment with clopi-
dogrel the costs per quality adjusted life year gained
(QALY) was 12.000 €. According to the established
willingness to pay levels in Spain (6.000–12.000 €), the
cost-effectiveness ratio for clopidogrel was shown to
be within the accepted ranges. A sensitivity analysis
showed costs per QALY ranging for a high-risk patient
from 5.000 € to 30.000 € for a low risk case.
For Switzerland, Frei et al. calculated based on the
CURE data 0.2 life years saving with clopidogrel treat-
ment [37]. The ICER of clopidogrel and ASA over
ASA alone were found to be CHF 3.810. The authors
concluded a comparable cost-effectiveness profile com-
pared to other cardiovascular therapies.
Bru¨ggenju¨rgen et al. based their results on the
German DRG-system (diagnosis related groups) [38].
In a DRG scenario the average total cost per pa-
tient came to 6.252 € for the clopidogrel group and to
5.789 € for placebo. The incremental costs efficacy ra-
tios ranged form 13.134 € for a per diem remuneration
to 23.035 € for DRG remuneration per prevented se-
vere life-threatening event. In a 2004 base case anal-
ysis (2500 €) the costs in the clopidogrel group were
5.367 € as compared to 4.996 in the placebo group.
The associated ICER was 18.458 € per life-threatening
event avoided. The authors calculated an acceptable
cost-effectiveness ratio for the German population,
even for the most conservative scenario (anticipation
of DRG-based remuneration).
For Austria Schwarz et al. predicted an incremental
survival of 0,12 years in patients with acute coronary
syndrome for 12 months treatment with clopidogrel
on top of standard therapy [39]. Evaluation of direct
and indirect disbursements indicated cost per life-year
saved of 4.146 €, regarded as cost-effective from the
Austrian societal view.
Cost-effectiveness studies for secondary
prevention of cardiovascular events with
clopidogrel
CAPRIE (Clopidogrel versus ASA in Patients at Risk
of Ischemic Events) was a randomized, blinded, inter-
national trial designed to assess the relative efficacy
and safety of clopidogrel (75 mg once daily) and ASA
(325 mg once daily) in reducing the risk of ischemic
stroke, MI, or vascular death in patients with recent
MI, stroke, or established peripheral arterial disease
[40]. CAPRIE studied patients that had known mani-
festations of thrombotic disease such as:
Recent MI [≤35 days] with chest pain ≥20 min, in-
creased cardiac enzymes or ECG changes or recent
ischemic stroke (≥1 week and ≤6 months) with neu-
rological deficit of atherosclerotic origin, neurological
signs persisting for ≥1 week, and CT or MRI to rule
out haemorrhage or an established peripheral arte-
rial disease (PAD) defined as either intermittent clau-
dication of presumed atherosclerotic origin and ankle
brachial index ≤0.85, or history of intermittent clau-
dication with previous leg amputation, reconstructive
surgery, or angioplasty.
The results of the CAPRIE study, involving 19.185
patients, established clopidogrel as a potent platelet
aggregation inhibitor in a broad group of patients at
risk of atherothrombotic events. In CAPRIE, clopido-
grel demonstrated an 8.7% (P = 0.045) overall risk re-
duction in the combined endpoint of first occurrence of
MI, stroke, or other vascular death. In a subgroup of
4.496 high-risk patients, followed after a second cardio-
vascular event (CVE), the clopidogrel group showed a
14.9% lower relative risk of recurrent CVE than the
patients in the ASA group [41]. The risk of a subse-
quent CVE was higher in patients who already had
two CVEs, even if the second or third event was not
necessarily the same like the first one. After one- and
three- year follow-up, patients receiving clopidogrel
were less likely than those receiving ASA to be hos-
pitalised for a CVE or to die from a CVE. One year af-
ter their second event, 16.1% of the clopidogrel group
and 18.5% of the ASA group had an ischemic stroke,
MI, or repeat hospitalisation for CVE. The compos-
ite end point for an ischemic stroke, MI, or vascular
death was reached in 8.8% of the clopidogrel-treated
patients and in 10.2% of the ASA group [41]. Three
years later, 32.7% of the clopidogrel patients and 36.6%
of the ASA patients showed another CVE. Vascular
death occurred in 20.4% of the clopidogrel patients and
in 23.8% of the ASA group. Consequently, treating 29
very high-risk patients with clopidogrel would prevent
one vascular death, MI, or ischemic stroke over three
years.
The statistical significance favouring clopidogrel
over ASA was marginal (P = 0.045, based on overall
incidence of primary outcome events: 9.8% for clopido-
grel versus 10.64% for ASA).
Gaspoz et al. investigated the cost-effectiveness of
ASA and clopidogrel for secondary prevention in pa-
tients with an ACS [10] (Table 5). The incremental
cost-effectiveness was estimated by using the Coro-
nary Heart Disease Policy Model (tracks patients sur-
viving the first month having coronary disease; cate-
gorizes patients of number, year, history of events and
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assigns the annual cost on an individual basis). The au-
thors performed a four-strategy scenario:
ASA for all eligible patients, ASA for all eligible pa-
tients plus clopidogrel for patients who were ineligible
for ASA, clopidogrel for all patients and two options
for the combination of ASA for all eligible patients plus
clopidogrel for all patients. The cost-effectiveness ratio
(25 years) for ASA was about 11.000 US $/QALY while
clopidogrel showed costs of 114.000 US $/QALY. The
authors concluded that the cost-effectiveness of clopi-
dogrel is currently unattractive for secondary preven-
tion of acute coronary syndrome, unless its use is re-
stricted to patients who are ineligible to ASA or the
price of clopidogrel would be reduced by 60 percent.
However 25 years of treatment without any price re-
duction in case of patent lost and the expected long
time period of compliance are questionable. In addition
the chosen population model shows a much lower risk
for the acute coronary syndrome than the population
in CURE.
Haldemann et al. included the costs of ischemic
strokes and primary non-fatal intracranial haemor-
rhages as well as MIs in their cost-effectiveness analy-
sis of the CAPRIE trial (Table 5). They determined 1.5
million CHF net cost savings of treating 1000 patients,
i.e. the incremental drug costs less the savings of ad-
verse outcomes. Patients receiving clopidogrel gained
63 life years per 1000 patients as compared to ASA
alone. They came to a justifiable economic perspective
for the use of clopidogrel by additional yearly costs
of 722 CHF per patient. Their analysis yield a cost-
effectiveness of 24.164 CHF nominal and 22.837 CHF
discounted per additional year of life saved.
Schleinitz et al. evaluated the cost-effectiveness of
clopidogrel and ASA for secondary prevention in pa-
tients with a prior MI, stroke or peripheral arterial dis-
ease [43] (Table 5). They used a Markov model based
analysis on the lifetime treatment of a 63-year-old pa-
tients. The event probabilities were derived from the
CAPRIE trial. Outcome measures included costs, life
expectancy in quality adjusted life-years (QALY’s), in-
cremental cost-effectiveness ratio (ICER) and events.
For patients presenting with peripheral arterial dis-
ease, clopidogrel could increase the life expectancy by
0.55 QALY at an incremental cost-effectiveness ratio
of 25.100 US $ per QALY, compared to ASA. In post
stroke patients, clopidogrel showed an increase of life
expectancy by 0.17 QALYs with a cost-utility ratio of
31.200 US $ per QALY. In post myocardial patients
ASA appeared to be less expensive and more effective
than clopidogrel. The authors pointed out that clopido-
grel provides an increase in quality adjusted life ex-
pectancy and costs that are in line with the traditional
societal limits for patients presenting either a periph-
eral arterial disease or a recent stroke. They could not
show an increased efficacy for clopidogrel following MI
compared to ASA, due to an increased rate of vascu-
lar death in clopidogrel treated patients in CAPRIE.
In a larger cohort (post hoc analysis CAPRIE), clopi-
dogrel was associated with a reduction in risk of 7.4%,
suggesting that clopidogrel does remain cost-effective
in patients that had a previous MI. For stroke patients
clopidogrel had a more favourable price than ASA. The
study is limited by the choice of events and interven-
tions (no bypass patients, atrial bypass patients, per-
cutaneous coronary interventions, admissions to hos-
pital for heart failure). The authors assumed a con-
stant probability of events over time, which is a con-
servative assumption; the occurrence of fewer events
is favouring the ASA arm. As the authors indicated,
these biases suggest a lower cost-effectiveness ratio
(than the base case) for clopidogrel in each sub group.
These findings indicate a benefit at disbursements that
is within the realms of possibility, based on clear ben-
efit for patients with peripheral vascular disease from
the CAPRIE study. The clinical advantage and cost-
effectiveness of clopidogrel in secondary prevention as
determined in the study by Schleinitz et al. has been
discussed controversially by Eriksson et al. [44].
Conclusion
Cost consciousness has become more and more impor-
tant over the last years for different therapy options,
especially in Europe.
In particular for clinicians running their own pri-
vate practise economical efficacy of prescriptions came
to the fore. On the other hand, there is the duty to give
patients the best possible treatment. This, against the
background of heavy ethical responsibility, which may
put physicians into a conflicting situation, requires con-
tinuous cost-effectiveness studies in the future. The
compendium of diverse health care systems justifies
the use of clopidogrel in the accepted indications also
from an economic point of view. This review supports
the notion that clopidogrel has both a medical and an
economic benefit. On the basis of a majority of the re-
viewed studies the use of clopidogrel is warranted and
the range of costs-effectiveness ratios were well within
the range of other accepted medical interventions.
Nevertheless limitations of cost-effectiveness studies
have to be taken in account before introducing new in-
dications for drugs therapies.
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